 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"warfarin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: WARFARIN: drug_interactions: [0m[1;31m7[0m[31m DRUG INTERACTIONS Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical [0m[1;31m([0m[31mherbal[0m[1;31m)[0m[31m products, and inhibitors and inducers of [0m
[31mCYP2C9, 1A2, or 3A4. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Consult labeling of all concurrently used drugs for complete information about interactions with warfarin sodium or increased risks for bleeding. [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7.1[0m[31m General [0m
[31mInformation Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism [0m[1;31m([0m[31mimpaired[0m
[31mhemostasis, reduced clotting factor synthesis[0m[1;31m)[0m[31m, competitive antagonism [0m[1;31m([0m[31mvitamin K[0m[1;31m)[0m[31m, and alteration of the physiologic control loop for vitamin K metabolism [0m[1;31m([0m[31mhereditary resistance[0m[1;31m)[0m[31m. Pharmacokinetic [0m
[31mmechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. WARFARIN: drug_interactions: It is important to note that some[0m
[31mdrugs may interact by more than one mechanism. More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, [0m
[31mincluding drugs intended for short-term use [0m[1;31m([0m[31me.g., antibiotics, antifungals, corticosteroids[0m[1;31m)[0m[31m [0m[1;31m[[0m[31m see Boxed Warning [0m[1;31m][0m[31m. Consult the labeling of all concurrently used drugs to obtain further information [0m
[31mabout interactions with warfarin sodium or adverse reactions pertaining to bleeding. [0m[1;31m7.2[0m[31m CYP450 Interactions CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, [0m
[31m1A2, and 3A4. The more potent warfarin S -enantiomer is metabolized by CYP2C9 while the R -enantiomer is metabolized by CYP1A2 and 3A4. WARFARIN: drug_interactions: Inhibitors of CYP2C9, 1A2, and/or [0m
[31m3A4 have the potential to increase the effect [0m[1;31m([0m[31mincrease INR[0m[1;31m)[0m[31m of warfarin by increasing the exposure of warfarin. Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect [0m[1;31m([0m[31mdecrease[0m
[31mINR[0m[1;31m)[0m[31m of warfarin by decreasing the exposure of warfarin. Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table [0m[1;31m2[0m[31m ; however, this list should not be considered all-inclusive. [0m
[31mConsult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential should be considered when starting, [0m
[31mstopping, or changing dose of concomitant medications. WARFARIN: drug_interactions: Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. Table [0m[1;31m2[0m[31m: Examples of [0m
[31mCYP450 Interactions with Warfarin Enzyme Inhibitors Inducers CYP2C9 amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, [0m
[31msulfinpyrazone, tigecycline, voriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, [0m
[31menoxacin, famotidine, fluvoxamine WARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, [0m
[31mticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, [0m
[31matazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, [0m
[31mfosamprenav WARFARIN: drug_interactions: ir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, [0m
[31mranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, [0m
[31mnafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN:[0m
[31mdrug_interactions: Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: [0m
[31mdrug_interactions: Table [0m[1;31m3[0m[31m: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents[0m
[31maspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, [0m
[31mketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, [0m
[31mparoxetine, sertraline, venlaf WARFARIN: drug_interactions: axine, vilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or [0m
[31mantifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic [0m
[31mor antifungal in patients taking warfarin. [0m[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m Products and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, [0m
[31mwell-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with [0m
[31mbotanical medicinal preparations, the amount of active ingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals [0m
[31mmay cause bleeding events when taken alone [0m[1;31m([0m[31me.g.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy Risk Summary Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of [0m
[31mthromboembolism, and for whom the benefits of warfarin sodium may outweigh the risks [0m[31m . Warfarin sodium can cause fetal harm. Exposure to warfarin during the first trimester of pregnancy caused a [0m
[31mpattern of congenital malformations in about [0m[1;31m5[0m[31m% of exposed offspring. Because these data were not collected in adequate and well-controlled studies, this incidence of major birth defects is not an [0m
[31madequate basis for comparison to the estimated incidences in the control group or the U.S. general population and may not reflect the incidences observed in practice. Consider the benefits and risks [0m
[31mof warfarin sodium and possible risks to the fetus when prescribing warfarin sodium to a pregnant woman. WARFARIN: pregnancy: Adverse outcomes in pregnancy occur regardless of the health of the mother[0m
[31mor the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk [0m
[31mof major birth defects and miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions In humans, warfarin [0m
[31mcrosses the placenta, and concentrations in fetal plasma approach the maternal values. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in [0m
[31mabout [0m[1;31m5[0m[31m% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses [0m[1;31m([0m[31mchondrodysplasia punctata[0m[1;31m)[0m[31m and growth retardation [0m[1;31m([0m[31mincluding low birth [0m
[31mweight[0m[1;31m)[0m[31m. WARFARIN: pregnancy: Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker [0m
[31mmalformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse [0m
[31mpregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [0m[31m .         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions to warfarin sodium are discussed in greater detail in other sections of the labeling: Hemorrhage [0m[31m [0m
[31mTissue Necrosis [0m[31m Calciphylaxis [0m[31m Acute Kidney Injury [0m[31m Systemic Atheroemboli and Cholesterol Microemboli [0m[31m Limb Ischemia, Necrosis, and Gangrene in Patients with HIT and HITTS [0m[31m Other Clinical Settings [0m
[31mwith Increased Risks [0m[31m Other adverse reactions to warfarin sodium include: Immune system disorders: hypersensitivity/allergic reactions [0m[1;31m([0m[31mincluding urticaria and anaphylactic reactions[0m[1;31m)[0m[31m Vascular [0m
[31mdisorders: vasculitis Hepatobiliary disorders: hepatitis, elevated liver enzymes. Cholestatic hepatitis has been associated with concomitant administration of warfarin sodium and ticlopidine. [0m
[31mGastrointestinal disorders: nausea, vomiting, diarrhea, taste perversion, abdominal pain, flatulence, bloating Skin disorders: rash, dermatitis [0m[1;31m([0m[31mincluding bullous eruptions[0m[1;31m)[0m[31m, pruritus, alopecia [0m
[31mRespiratory disorders: tracheal or tracheobronchial calcification General disorders: chills Most common adverse reactions to warfarin sodium are fatal and nonfatal hemorrhage from any tissue or organ.[0m
[31mWARFARIN: adverse_reactions: [0m[1;31m([0m[31m [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Teva at [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m838[0m[31m-[0m[1;31m2872[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: spl_medguide: MEDICATION GUIDE Dispense with Medication Guide available at: www.tevausa.com/medguides Warfarin [0m[1;31m([0m[31mwar' far in[0m[1;31m)[0m[31m Sodium [0m[1;31m([0m[31msoe' dee um[0m[1;31m)[0m[31m Tablets What is the most important [0m
[31minformation I should know about warfarin sodium tablets? Warfarin sodium tablets can cause bleeding which can be serious and sometimes lead to death. This is because warfarin sodium tablets are a [0m
[31mblood thinner medicine that lowers the chance of blood clots forming in your body. WARFARIN: spl_medguide: You may have a higher risk of bleeding if you take warfarin sodium tablets and: are [0m[1;31m65[0m[31m years [0m
[31mof age or older have a history of stomach or intestinal bleeding have high blood pressure [0m[1;31m([0m[31mhypertension[0m[1;31m)[0m[31m have a history of stroke, or “mini-stroke” [0m[1;31m([0m[31mtransient ischemic attack or TIA[0m[1;31m)[0m[31m have serious [0m
[31mheart disease have a low blood count or cancer have had trauma, such as an accident or surgery have kidney problems take other medicines that increase your risk of bleeding, including: a medicine that[0m
[31mcontains heparin other medicines to prevent or treat blood clots non-steroidal anti-inflammatory drugs [0m[1;31m([0m[31mNSAIDs[0m[1;31m)[0m[31m take warfarin sodium for a long time. Warfarin sodium is the active ingredient in [0m
[31mwarfarin sodium tablets. Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above. WARFARIN: [0m
[31mspl_medguide: Many other medicines can interact with warfarin sodium tablets and affect the dose you need or increase warfarin sodium tablets side effects. Do not change or stop any of your medicines [0m
[31mor start any new medicines before you talk to your healthcare provider. Do not take other medicines that contain warfarin sodium while taking warfarin sodium tablets. Get your regular blood test to [0m
[31mcheck for your response to warfarin sodium tablets. This blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR numbers [0m
[31mare best for you. Your dose of warfarin sodium tablets will be adjusted to keep your INR in a target range for you. WARFARIN: spl_medguide: Call your healthcare provider right away if you get any of [0m
[31mthe following signs or symptoms of bleeding problems: pain, swelling, or discomfort headaches, dizziness, or weakness unusual bruising [0m[1;31m([0m[31mbruises that develop without known cause or grow in size[0m[1;31m)[0m[31m [0m
[31mnosebleeds bleeding gums bleeding from cuts takes a long time to stop menstrual bleeding or vaginal bleeding that is heavier than normal pink or brown urine red or black stools coughing up blood [0m
[31mvomiting blood or material that looks like coffee grounds Some foods and beverages can interact with warfarin sodium tablets and affect your treatment and dose. Eat a normal, balanced diet. Talk to [0m
[31myour healthcare provider before you make any diet changes. Do not eat large amounts of leafy, green vegetables. Leafy, green vegetables contain vitamin K. Certain vegetable oils also contain large [0m
[31mamounts of vitamin K. Too much vitamin K can lower the effect of warfarin sodium tablets. Always tell all of your healthcare providers that you take warfarin sodium tablets.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: spl_medguide_table: [0m[31mCode[0m[31m=[0m[31m"bold"[0m[31m>What is the most important information I should know about warfarin sodium tablets?[0m[1;31m<[0m[31m/[0m[31mcontent[0m[31m><paragraph>Warfarin sodium tablets can cause bleeding [0m
[31mwhich can be serious and sometimes lead to death. This is because warfarin sodium tablets are a blood thinner medicine that lowers the chance of blood clots forming in your body. WARFARIN: [0m
[31mspl_medguide_table: <[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>You may have a higher risk of bleeding if you take warfarin sodium tablets and: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Circle"[0m[31m><item>are [0m[1;31m65[0m[31m years of age or older <[0m[31m/[0m[31mitem[0m[31m><item>have a history of stomach or intestinal bleeding <[0m[31m/[0m[31mitem[0m[31m><item>have high blood pressure [0m[1;31m([0m[31mhypertension[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have a history of [0m
[31mstroke, or &#x201C;mini-stroke&#x201D; [0m[1;31m([0m[31mtransient ischemic attack or TIA[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have serious heart disease <[0m[31m/[0m[31mitem[0m[31m><item>have a low blood count or cancer <[0m[31m/[0m[31mitem[0m[31m><item>have had trauma, such as an[0m
[31maccident or surgery <[0m[31m/[0m[31mitem[0m[31m><item>have kidney problems <[0m[31m/[0m[31mitem[0m[31m><item>take other medicines that increase your risk of bleeding, including: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Square"[0m[31m><item>a medicine [0m
[31mthat contains heparin <[0m[31m/[0m[31mitem[0m[31m WARFARIN: spl_medguide_table: ><item>other medicines to prevent or treat blood clots <[0m[31m/[0m[31mitem[0m[31m><item>non-steroidal anti-inflammatory drugs [0m[1;31m([0m[31mNSAIDs[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>take warfarin sodium for a long time. Warfarin sodium is the active ingredient in warfarin sodium tablets. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above. [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Many other medicines can interact with warfarin sodium tablets and affect the dose you need or increase warfarin sodium tablets side effects. Do not change or stop any[0m
[31mof your medicines or start any new medicines before you talk to your healthcare provider. <[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not take other medicines that contain warfarin sodium [0m
[31mwhile taking warfarin sodium tablets. WARFARIN: spl_medguide_table: content><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Get your regular blood test to check[0m
[31mfor your response to warfarin sodium tablets. <[0m[31m/[0m[31mcontent[0m[31m>This blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR [0m
[31mnumbers are best for you. Your dose of warfarin sodium tablets will be adjusted to keep your INR in a target range for you. WARFARIN: spl_medguide_table: <[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Call [0m
[31myour healthcare provider right away if you get any of the following signs or symptoms of bleeding problems: <[0m[31m/[0m[31mcontent[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Circle"[0m[31m><item>pain, swelling, or discomfort [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><item>headaches, dizziness, or weakness <[0m[31m/[0m[31mitem[0m[31m><item>unusual bruising [0m[1;31m([0m[31mbruises that develop without known cause or grow in size[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>nosebleeds <[0m[31m/[0m[31mitem[0m[31m><item>bleeding gums [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><item>bleeding from cuts takes a long time to stop <[0m[31m/[0m[31mitem[0m[31m><item>menstrual bleeding or vaginal bleeding that is heavier than normal <[0m[31m/[0m[31mitem[0m[31m><item>pink or brown urine <[0m[31m/[0m[31mitem[0m[31m><item>red or black [0m
[31mstools <[0m[31m/[0m[31mitem[0m[31m><item>coughing up blood <[0m[31m/[0m[31mitem[0m[31m><item>vomiting blood or material that looks like coffee grounds <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Some foods and beverages can interact [0m
[31mwith         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation. [0m
[31mDiscontinue warfarin sodium and consider alternative anticoagulants if necessary. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Calciphylaxis: Fatal and serious cases have occurred. Discontinue warfarin sodium and consider alternative [0m
[31manticoagulation therapy. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m Acute kidney injury may occur during episodes of excessive anticoagulation and hematuria. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Systemic atheroemboli and cholesterol microemboli: Some cases have [0m
[31mprogressed to necrosis or death. Discontinue warfarin sodium if such emboli occur. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m Heparin-induced thrombocytopenia [0m[1;31m([0m[31mHIT[0m[1;31m)[0m[31m: Initial therapy with warfarin sodium in HIT has resulted in cases of [0m
[31mamputation and death. WARFARIN: warnings_and_cautions: Warfarin sodium may be considered after platelet count has normalized. [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m [0m[1;31m)[0m[31m Pregnant women with mechanical heart valves: Warfarin sodium may [0m
[31mcause fetal harm; however, the benefits may outweigh the risks. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m Hemorrhage Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. Risk [0m
[31mfactors for bleeding include high intensity of anticoagulation [0m[1;31m([0m[31mINR [0m[1;31m>[0m[31m [0m[1;31m4[0m[1;31m)[0m[31m, age greater than or equal to [0m[1;31m65[0m[31m, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, [0m
[31mcerebrovascular disease, anemia, malignancy, trauma, renal impairment, certain genetic factors [0m[31m , certain concomitant drugs [0m[31m , and long duration of warfarin therapy. Perform regular monitoring of INR [0m
[31min all treated patients. WARFARIN: warnings_and_cautions: Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration [0m
[31mof therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding. Drugs, dietary changes, and other factors affect INR [0m
[31mlevels achieved with warfarin sodium therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [0m[31m . Instruct [0m
[31mpatients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m[1;31m5.2[0m[31m Tissue Necrosis Warfarin sodium can cause necrosis and/or gangrene of skin and other[0m
[31mtissues, which is an uncommon but serious risk [0m[1;31m([0m[31m<[0m[1;31m0.1[0m[31m%[0m[1;31m)[0m[31m. WARFARIN: warnings_and_cautions: Necrosis may be associated with local thrombosis and usually appears within a few days of the start of warfarin[0m
[31msodium therapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported. Careful clinical evaluation is required to [0m
[31mdetermine whether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin [0m
[31msodium therapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.3[0m[31m Calciphylaxis Warfarin sodium can cause fatal and serious calciphylaxis or calcium [0m
[31muremic arteriolopathy, which has been reported in patients with and without end-stage renal disease. When calciphylaxis is diagnosed in these patients, discontinue warfarin sodium and treat [0m
[31mcalciphylaxis as appropriate. Consider alternative anticoagulation therapy. [0m[1;31m5[0m[31m. WARFARIN: warnings_and_cautions: [0m[1;31m4[0m[31m Acute Kidney Injury In patients with altered glomerular integrity or with a history of[0m
[31mkidney disease, acute kidney injury may occur with warfarin sodium, possibly in relation to episodes of excessive anticoagulation and hematuria [0m[31m . More frequent monitoring of anticoagulation is [0m
[31madvised in patients with compromised renal function. [0m[1;31m5.5[0m[31m Systemic Atheroemboli and Cholesterol Microemboli Anticoagulation therapy with warfarin sodium may enhance the release of atheromatous plaque [0m
[31memboli. Systemic atheroemboli and cholesterol microemboli can present with a variety of signs and symptoms depending on the site of embolization. The most commonly involved visceral organs are the [0m
[31mkidneys followed by the pancreas, spleen, and liver. Some cases have progressed to necrosis or death. A distinct syndrome resulting from microemboli to the feet is known as “purple toes syndrome. [0m
[31mWARFARIN: warnings_and_cautions: Discontinue warfarin sodium therapy if such phenomena are observed. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.6[0m[31m Limb Ischemia, [0m
[31mNecrosis, and Gangrene in Patients with HIT and HITTS Do not use warfarin sodium as initial therapy in patients with heparin-induced thrombocytopenia [0m[1;31m([0m[31mHIT[0m[1;31m)[0m[31m and with heparin-induced thrombocytopenia [0m
[31mwith thrombosis syndrome [0m[1;31m([0m[31mHITTS[0m[1;31m)[0m[31m. Cases of limb ischemia, necrosis, and gangrene have occurred in patients with HIT and HITTS when heparin treatment was discontinued and warfarin therapy was started [0m
[31mor continued. In some patients, sequelae have included amputation of the involved area and/or death. Treatment with warfarin sodium may be considered after the platelet count has normalized. [0m[1;31m5.7[0m[31m Use [0m
[31min Pregnant Women with Mechanical Heart Valves Warfarin sodium can cause fetal harm when administered to a pregnant woman. WARFARIN: warnings_and_cautions: While warfarin sodium is contraindicated [0m
[31mduring pregnancy, the potential benefits of using warfarin sodium may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism. In those individual [0m
[31msituations, the decision to initiate or continue warfarin sodium should be reviewed with the patient, taking into consideration the specific risks and benefits pertaining to the individual patient’s [0m
[31mmedical situation, as well as the most current medical guidelines. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations [0m[1;31m([0m[31mwarfarin embryopathy and [0m
[31mfetotoxicity[0m[1;31m)[0m[31m, fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this [0m
[31mdrug, the patient should be apprised of the potential hazard to a fetus [0m[31m . [0m[1;31m5[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: openfda: spl_set_id         [0m
[31mSOURCE:WARFARIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the WARFARIN label does not specifically mention an increased risk of acute liver injury. However, it does list hepatitis and elevated liver enzymes as possible [0m
[32madverse reactions, indicating that liver issues can occur, although the frequency or risk level is not specified. It is important to monitor patients for signs of liver damage when taking warfarin.[0m

[32mSOURCE: WARFARIN label[0m
[32mEXTRACT_START_END: Hepatobiliary disorders: hepatitis, elevated liver enzymes[0m[32m...[0m[32massociated with concomitant administration of warfarin sodium and ticlopidine.[0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the WARFARIN label does not [0m
[34mspecifically mention an increased risk of acute liver injury. However, it does list hepatitis and elevated liver enzymes as possible adverse reactions, indicating that liver issues can occur, although[0m
[34mthe frequency or risk level is not specified. It is important to monitor patients for signs of liver damage when taking warfarin.[0m

[34mSOURCE: WARFARIN label[0m
[34mEXTRACT_START_END: Hepatobiliary disorders: hepatitis, elevated liver enzymes[0m[34m...[0m[34massociated with concomitant administration of warfarin sodium and ticlopidine.[0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if WARFARIN increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the WARFARIN label does not specifically mention an increased risk of acute liver injury, but it does list hepatitis and elevated liver enzymes as possible adverse [0m
[32mreactions."[0m[32m,[0m
[32m      [0m[32m"The frequency or risk level of these liver issues is not specified in the label."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The WARFARIN label does not specifically mention an increased risk of acute liver injury, but it does list hepatitis and elevated liver enzymes as possible adverse reactions. This [0m
[32mindicates that liver issues can occur with the use of WARFARIN, although the exact frequency or risk level is not detailed in the label. Therefore, while there is a potential for liver-related side [0m
[32meffects, the degree of risk for acute liver injury specifically is not clearly defined based on the label information."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does WARFARIN increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if WARFARIN increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the WARFARIN label does not specifically mention an increased risk of acute liver injury, but it does list hepatitis and elevated liver enzymes as possible adverse [0m
[34mreactions."[0m[34m,[0m
[34m      [0m[34m"The frequency or risk level of these liver issues is not specified in the label."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The WARFARIN label does not specifically mention an increased risk of acute liver injury, but it does list hepatitis and elevated liver enzymes as possible adverse reactions. This [0m
[34mindicates that liver issues can occur with the use of WARFARIN, although the exact frequency or risk level is not detailed in the label. Therefore, while there is a potential for liver-related side [0m
[34meffects, the degree of risk for acute liver injury specifically is not clearly defined based on the label information."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does WARFARIN increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if WARFARIN increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that the WARFARIN label does not specifically mention an increased risk of acute liver injury, but it does list hepatitis and elevated liver enzymes as possible adverse [0m
[31mreactions.[0m
[1;31m3[0m[31m. The frequency or risk level of these liver issues is not specified in the label.[0m
[31m        -----[0m
[31m        Final answer: The WARFARIN label does not specifically mention an increased risk of acute liver injury, but it does list hepatitis and elevated liver enzymes as possible adverse reactions. [0m
[31mThis indicates that liver issues can occur with the use of WARFARIN, although the exact frequency or risk level is not detailed in the label. Therefore, while there is a potential for liver-related [0m
[31mside effects, the degree of risk for acute liver injury specifically is not clearly defined based on the label information.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe WARFARIN label does not specifically mention an increased risk of acute liver injury, but it does list hepatitis and elevated liver enzymes as possible adverse reactions. This indicates that liver[0m
[32missues can occur with the use of WARFARIN, although the exact frequency or risk level is not detailed in the label. Therefore, while there is a potential for liver-related side effects, the degree of [0m
[32mrisk for acute liver injury specifically is not clearly defined based on the label information.[0m
